Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-positive Breast Cancer × trastuzumab deruxtecan × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 51 Neoplasm Metastasis 21 Stomach Neoplasms 12 Carcinoma, Non-Small-Cell Lung 11 Colorectal Neoplasms 8 Neoplasms 7 Brain Neoplasms 7 Triple Negative Breast Neoplasms 5 Adenocarcinoma 5 Recurrence 3 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Advanced Solid Tumor 3 Salivary Gland Neoplasms 2 Pancreatic Neoplasms 2 Meningeal Carcinomatosis 2 Esophageal Neoplasms 2 Breast Cancer With Brain Metastasis 2 Uterine Neoplasms 1 Solid Cancer 1 Sarcoma 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteosarcoma 1 Neoplasm, Residual 1 Melanoma 1 Lung Neoplasms 1 HER2-positive Gastric Cancer 1 HER2-positive Breast Cancer 1 HER2-negative Breast Cancer 1

Interventions

Trastuzumab 26 pertuzumab 13 Docetaxel 13 pyrotinib 11 Paclitaxel 7 Capecitabine 5 Carboplatin 4 tucatinib 3 Ado-Trastuzumab Emtansine 3 atezolizumab 2 Protons 2 Fulvestrant 2 trastuzumab deruxtecan 1 pegfilgrastim 1 palbociclib 1 neratinib 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Fluorodeoxyglucose F18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05982678 2025-11-26

ANISE

The Netherlands Cancer Institute

Phase 2 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡